Physiological Responses to Relative Hypoglycemia in Uncontrolled Type 2 Diabetes Mellitus: A Pilot Study

Abstract

Objective

To evaluate the hormonal, cardiac, and neuronal responses during relative hypoglycemia in uncontrolled type 2 diabetes mellitus patients.

Methods

Fifteen uncontrolled type 2 diabetes mellitus patients underwent insulin infusion at 0.05 U/kg/h, titrated at 1 U/h every 10 minutes, until they developed symptoms of hypoglycemia with a glucose level >3.9 mmol/L. Blood samples for glucose, cortisol, glucagon, and epinephrine, as well as electrocardiogram and electroencephalogram readings, were taken before insulin infusion and repeated once hypoglycemic symptoms developed. Data were analyzed using paired t-tests and Wilcoxon signed-rank tests. The p-value of <0.05 was considered significant.

Results

The median glucose level during relative hypoglycemia was 6.7 (4.3–7.3) mmol/L, and 86.7% of patients experienced autonomic symptoms. The mean glucagon level was significantly higher at baseline than during relative hypoglycemia (4,842.93 vs. 4,300.13 pg/mL, p = 0.041). During relative hypoglycemia, 66.7 and 60% of patients had declined glucagon and cortisol levels, respectively. Meanwhile, 53.3% of patients experienced an increase in epinephrine levels. There was no significant change in cortisol and epinephrine levels during relative hypoglycemia compared to baseline. The electroencephalogram showed generalized background attenuation in eight patients, and none had electrocardiogram changes.

Conclusion

This study demonstrates that relative hypoglycemia, in uncontrolled type 2 diabetes mellitus, only leads to autonomic symptoms without significant counterregulatory hormonal, cardiovascular, and neurological changes. Clinically, recognizing relative hypoglycemia is crucial to avoid misinterpreting it as true hypoglycemia and to highlight its potential role in causing impaired patient awareness of subsequent true hypoglycemic episodes. The small sample size and potential confounding factors warrant cautious interpretation, and larger studies are needed to confirm these findings and to develop strategies for monitoring and managing relative hypoglycemia in clinical practice.

Keywords

relative hypoglycemia - type 2 diabetes mellitus - cortisol - glucagon - epinephrine - electroencephalogram

Introduction

Hypoglycemia is a common and potentially serious complication of diabetes management. The incidence of hypoglycemic episodes in people with type 2 diabetes mellitus (T2D) ranges from 2.2 to 3.7 events per month, and 46.5% T2D patients experience recurrent episodes.[1] Traditionally, hypoglycemia is defined based on Whipple's triad: typical hypoglycemic symptoms, plasma glucose level <3.9 mmol/L, and symptoms resolved following glucose normalization.[2] In response to hypoglycemia, counter-regulatory hormones (glucagon, epinephrine, and cortisol) act to restore euglycemia via gluconeogenesis and glycogenolysis.[3] [4] [5] [6] [7] The severity of hypoglycemia is classified into three levels. Level 1 is defined as plasma glucose below 3.9 mmol/L but remains ≥3.0 mmol/L, a threshold that normally triggers neuroendocrine responses. In diabetes, this level is considered clinically significant regardless of symptoms. Level 2 is characterized by glucose <3.0 mmol/L, with neuroglycopenic symptoms becoming more pronounced and requiring immediate correction. Level 3 represents severe hypoglycemia, defined not by a specific glucose value but by altered mental or physical function necessitating assistance from another person to restore normoglycemia.[8]

Symptoms of hypoglycemia include autonomic symptoms (trembling, palpitations, sweating, anxiety, or hunger) and neuroglycopenic symptoms (difficulty concentrating, confusion, weakness or stroke-like symptoms, drowsiness, or headache).[2]

Hypoglycemia significantly affects both the brain and cardiovascular system. Recurrent hypoglycemia is associated with cognitive decline and increased risk of dementia, likely due to neuronal injury in glucose-sensitive brain regions such as the cortex and hippocampus.[9] [10] Electroencephalogram (EEG) studies show reduced frequency and increased amplitude of brain activity when blood glucose levels drop below 3.5 mmol/L.[11]

Cardiovascular effects, including systemic inflammation, endothelial dysfunction, abnormalities in coagulation and fibrinolysis, arrhythmias, electrocardiographic (ECG) abnormalities such as QT interval (QTc) prolongation, ST-segment depression, and T-wave flattening, are primarily driven by catecholamine surges.[12] [13] [14] [15] [16] Interestingly, certain patients with poorly controlled diabetes experience classical hypoglycemic symptoms despite normal glucose levels (≥3.9 mmol/L). This phenomenon is known as relative hypoglycemia or pseudohypoglycemia.[17] Despite its clinical relevance, the physiological impact of relative hypoglycemia remains poorly understood. To date, no published studies have comprehensively examined the hormonal, neurological, and cardiovascular responses associated with relative hypoglycemia in this population.

Therefore, this study aimed to assess changes in cortisol, glucagon, and epinephrine levels, as well as alterations in EEG and ECG at baseline and during episodes of relative hypoglycemia in patients with uncontrolled T2D.

Method

This was a cross-sectional pilot study done from July 2020 to June 2021. Patients were recruited from the endocrine clinic, Hospital Canselor Tuanku Muhriz (HCTM). The patient selection was based on purposive sampling with no control group included. The study was approved by the Research Ethics Committee of Universiti Kebangsaan Malaysia and funded through a fundamental grant (research code: FF-2020-360). Informed written consent was obtained from patients who experienced relative hypoglycemia. This is defined as individuals having had at least two episodes of hypoglycemic symptoms (such as giddiness, tremor, sweating, palpitation, hunger, nausea, tingling, weakness, vision changes, headache, confusion, drowsiness, and difficulty speaking and concentrating) with a documented blood glucose level >3.9 mmol/L and the symptoms resolved after taking a meal. The study was conducted in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and complied with the Declaration of Helsinki of 1964 and its subsequent amendments. Fifteen uncontrolled T2D patients (HbA1c level greater than 8%), aged between 18 and 60 years, were recruited. None of the patients has ischemic heart disease, epilepsy, chronic kidney disease with eGFR <60 mL/min/1.73 m², a history of documented hypoglycemia (blood glucose < 3.9 mmol/L), or is on prolonged steroid or traditional medications.

Procedure

The procedure was performed at the endocrine laboratory, HCTM, which is equipped with emergency facilities and has medical personnel present throughout the procedure. All patients had fasted overnight (for at least 8 hours) and the morning dose of the antidiabetic medications was omitted ([Fig. 1]). Each patient was assessed for hypoglycemic symptoms before the procedure using a hypoglycemia symptom checklist. Two cannulas, sized 22G and 20G, were inserted at the left and right antecubital fossa for insulin infusion and blood taking, respectively. A three-way stop cock was connected to the left cannula for insulin administration as an emergency measure if the patient's blood glucose dropped to <3.9 mmol/L. Ten mL of blood was withdrawn from the right cannula for baseline blood glucose, cortisol, glucagon, and epinephrine levels. The echocardiogram (ECHO), ECG, and EEG were done at baseline. The ECG and EEG leads were attached to the patient throughout the procedure. Short-acting insulin (Actrapid) was infused intravenously at 0.05 U/kg/h, and the dose was titrated by 1 U/kg/h every 10 minutes. The glucose level was monitored every 5 minutes using an Accu-Chek glucometer. Insulin infusion was stopped once the patient developed symptoms of hypoglycemia, and blood was drawn to determine the glucose level. If the glucose level was >3.9 mmol/L, all procedures, including blood taking, ECG, and EEG, were repeated. Oral glucose was administered as needed to reverse the symptoms, and the glucose level was monitored every 10 minutes for a total of 60 minutes. The patient was kept in the laboratory for monitoring until they became entirely asymptomatic and fulfilled the safe discharge criterion checklist.

Fig. 1 Flow chart of the study procedure.

The ECG was analyzed for heart rate, ST depression, T-wave inversion, ectopic beats, and QT interval. The EEG was monitored throughout the procedure and analyzed by a certified neurologist to detect any changes in amplitude, frequency, the presence of delta and theta wave activities, or attenuation of EEG waves.

Cortisol Assay

Serum cortisol assay was taken and centrifuged for 10 minutes at 3,000 rpm using commercially available chemiluminescent microparticle immunoassay with ARCHITECT Cortisol assay (detection range: 27.59–1,650 nmol/L, with a limit of detection of less than 22.07 nmol/L).

Glucagon and Epinephrine Assay

Serum glucagon and epinephrine were taken and centrifuged for 15 minutes at 2,000 rpm. The sera were processed using an ELISA Kit from Elabscience (Catalogue No: E-EL-0045/E-EL-H2237). The ELISA Kit employs the competitive ELISA principle, with a sensitivity value of 18.75 pg/mL and a detection range of 31.25 to 2,000 pg/mL for both glucagon and epinephrine. All samples were assayed in the same batch analysis to avoid inter-assay variation.

Statistical Analysis

The sample size was calculated using a power and sample size calculation. Data were analyzed using the Statistical Software Product and Services (SPSS) version 26.0. Normally distributed data were expressed as mean ± standard deviation, while nonnormally distributed numerical data were expressed as median ± interquartile range. The analysis of the association between numerical and categorical data was performed using a paired t-test and a Wilcoxon signed-rank test, depending on sample distribution. The p-value of <0.05 was considered significant.

Results

A total of 15 uncontrolled T2D patients were recruited, with a mean age of 47.27 ± 9.59 years, ranging from 31 to 59 years old. The median duration of T2D was 5 years (range, 3 years). The mean HbA1c and fasting glucose levels were 10.4 ± 1.4% and 11.25 ± 3.58 mmol/L, respectively. The median glucose level during relative hypoglycemia was 6.70 (4.5–7.3) mmol/L. Other demographic data are shown in [Table 1]. During relative hypoglycemia, 86.7% (13) of patients had autonomic symptoms, mainly experiencing hunger, palpitations, and sweating. Only 13.3% (2) of patients had both autonomic and neuroglycopenic symptoms, namely, giddiness ([Fig. 2]).

Table 1 Demographic and biochemical data of the study population

Parameter	Mean ± SD
Age (year)	47.27 ± 9.59
Weight (kg)	76.67 ± 12.19
BMI (kg/m2)	30.2 ± 4.29
Medications: (n, %)
Insulin	2 (13.3%)
OHA	5 (33.3%)
Insulin and OHA	8 (53.3%)
OHA (n, %)
Biguanide (metformin)	13 (86.7%)
SGLT2 inhibitor (dapagliflozin)	5 (33.3%)
Sulphonylureas (gliclazide)	2 (13.3%)
DPP4 inhibitor (vildagliptin)	2 (13.3%)
Insulin (n, %)
Human insulin	11 (73.3%)
Glargine	4 (26.7%)
Premixed Ryzodeg	1 (6.7%)
ECG	Sinus rhythm
ECHO	Ejection fraction more than 60% with no regional wall motion hypokinesia
Pre-insulin infusion
Blood glucose at baseline (mmol/L)	9.69 ± 2.25
Post- insulin infusion
Blood glucose during relative hypoglycemia (mmol/L)	6.70 (4.5–7.3)[a]

Abbreviations: BMI, body mass index; DPP4 inhibitor, dipeptidyl peptidase 4 inhibitor; ECG, electrocardiogram; ECHO, echocardiogram; OHA, oral hypoglycemic agent; SD, standard deviation; SGLT2 inhibitor, sodium-glucose transport protein 2 inhibitor.

^a All values are expressed in mean ± SD, except blood glucose during relative hypoglycemia, expressed in median (IQR).

Fig. 2 Autonomic and neuroglycopenic symptoms during relative hypoglycemia.

The mean glucagon level was significantly higher at baseline compared to relative hypoglycemia (4,842.93 vs. 4,300.13 pg/mL, p = 0.041). Approximately 66.7% (10) of patients experienced a decrement in glucagon levels during relative hypoglycemia. Approximately 53.3% (8) of patients experienced an increase in epinephrine levels during relative hypoglycemia, while 46.7% (7) of patients had a decrease in epinephrine levels. During relative hypoglycemia, 60% (9) had a reduced cortisol level, 33.3% (5) had an increment, and only 6.7% (1) of patients had no difference ([Fig. 3]). However, the difference in epinephrine and cortisol levels between baseline and during relative hypoglycemia was statistically not significant, as shown in [Fig. 3].

Fig. 3 Hormone levels at baseline and during relative hypoglycemia.

The baseline EEG showed symmetrical and reactive posterior dominant alpha rhythm, ranging from 8 to 12 cycles per second in all 15 patients. Approximately 53.3% (8) had generalized attenuation in the EEG background during relative hypoglycemia. There was no generalized or focal slowing of the brain activity during relative hypoglycemia. There was no significant difference between EEG changes with cortisol (p = 0.556), glucagon (p = 0.645), and adrenaline (p = 0.406) levels. All baseline ECGs demonstrated a sinus rhythm with no ST changes. Similarly, during relative hypoglycemia, none of them had ST depression, T wave inversion, prolonged QT interval, or arrhythmias.

Discussion

Relative hypoglycemia is a diabetes complication where the threshold for detecting and responding to low blood sugar levels is higher than normal. Under normal conditions, the response occurs when blood sugar drops to 3.9 mmol/L or below. The initial response involves the rapid secretion of glucagon and epinephrine, followed by cortisol to restore circulating glucose levels.[3] [4] [18] Activation of the sympathoadrenal system causes both adrenergic and cholinergic symptoms as well as neuroglycopenic symptoms once glucose supply to the brain is reduced.[18] The median glucose level when patients developed autonomic and neuroglycopenic symptoms of hypoglycemia was 6.7 mmol/L. This explains why our T2D patients are poorly controlled because they are reluctant to have tighter glycemic control as a result of their perceived hypoglycemic symptoms.

Lund demonstrated that in T2D patients, fasting and basal glucagon levels were elevated and failed to be suppressed upon ingestion of nutrients.[19] Hyperglucagonemia occurs due to insulin resistance and the diminished suppressive effect of insulin on the alpha cells in the pancreas, resulting in hypersensitivity to glucagon secretion and leading to hyperglycemia.[3] Boden et al also observed that basal glucagon concentrations were higher in patients with T2D than in controls.[20] All our patients had a high baseline glucagon level compared to levels during the episodes of relative hypoglycemia. We observed a reduction in glucagon levels during relative hypoglycemia, likely due to the exogenous insulin infusion, as physiological insulin would inhibit glucagon release.[21] This finding was not observed in definite hypoglycemia because the glucagon level would be elevated once glucose levels drop to less than 3.9 mmol/L.[3] [19]

Our study showed that 53.3% of our patients experienced an increase in epinephrine levels during relative hypoglycemia compared to their baseline levels. This finding was consistent with previous studies that showed an early release of epinephrine in hypoglycemia compared to other hormones.[3] [4] [22] Schwartz et al demonstrated that activation of epinephrine secretion in hypoglycemia occurred at a glucose level of 69 ± 2 mg/dL (3.45 mmol/L), which is higher than the glucose level needed to secrete glucagon (68 ± 2 mg/dL [3.4 mmol/L]) and cortisol (58 ± 3 mg/dL [2.9 mmol/L]).[3] A study by Mitrakou et al showed that the secretion of glucagon and epinephrine occurred at higher plasma glucose levels between 72 and 80 mg/dL (3.6–4.0 mmol/L).[4] Amiel et al observed that epinephrine release occurred at a glucose level of 3.15 mmol/L, which is higher than the levels of glucagon and cortisol at 2.75 mmol/L.[22] In our study, the stress and anxiety during the procedure could be the confounding factors for the increment of epinephrine levels during relative hypoglycemia.

Our study also showed normal cortisol levels at baseline in all patients, and 60% had cortisol decrement during relative hypoglycemia. Tesfaye and Seaquist showed that the cortisol secretion occurs approximately at a glucose level of 3.2 mmol/L.[23] However, studies by Amiel et al and Mitrakou et al demonstrated that the activation of serum cortisol occurs at lower glucose rates, 53 ± 2 mg/dL (2.65 mmol/L) and 55 ± 2 mg/dL (2.75 mmol/L), respectively.[4] [24] These findings were consistent with our study, in which cortisol release needs a lower glucose level to activate the adrenocorticotropic hormone secretion.

A previous study found that EEG signals began to appear at a glucose level of 3.3 mmol/L, characterized by a slow rhythm and a reduction in frequency, accompanied by diffuse theta and delta activities.[25] Pramming et al reported that no EEG changes would occur at blood glucose levels >3 mmol/L, but increased theta activity was observed when blood glucose levels were at 2.0 mmol/L.[26] In our study, 53% (8) of patients had generalized attenuation of EEG background during relative hypoglycemia, and five of them had a concomitant increment in epinephrine. The background attenuation of EEG is defined as background activity consisting of amplitudes less than 20 microvolts. This can be a nonspecific and low-amplitude EEG that can happen in an anxiety state.[27] None of our patients had diffuse or focal slowing in the EEG. In our study, those with background attenuation with concomitant elevated epinephrine levels were likely due to anxiety during the procedure rather than relative hypoglycemia. A previous study had shown that up to 9% of patients with anxiety states may have low voltage in their EEG.[28] None of our patients experienced any cardiac symptoms or ECG changes during relative hypoglycemia, in which sympathoadrenal counter-regulation was not activated; hence, there was no significant deleterious effect on the heart. Since this is only a pilot study, a multi-center, larger-scale study is required to elucidate the counterregulatory changes in relative hypoglycemia.

Conclusion

Our study showed that relative hypoglycemia only causes autonomic symptoms, without significant changes in the counterregulatory hormones and cardiovascular or neurological systems. The novelty of our study, albeit a pilot one, lies in examining the true changes that occur during relative hypoglycemia in T2D patients. Our study findings will provide a foundation for future research involving a larger cohort to explore the short- and long-term effects of relative hypoglycemia on hormonal, cardiovascular, and neurogenic responses. Hence, there is a need to develop strategies for monitoring and managing relative hypoglycemia in clinical practice.

Conflict of Interest

None declared.

Author Contribution

N.A.W.: conceptualization, formal analysis, funding acquisition, investigation, methodology, data curation, analysis, resources, supervision, and writing—review and editing. N.H.H.: data curation, formal analysis, investigation, methodology, and writing—original draft. C.S.K.: conceptualization, methodology, analysis, supervision, and writing—review and editing. S.A.S.: conceptualization, data curation, analysis, methodology, and writing—review and editing.

Compliance with Ethical Principles

The study was approved by the Research Ethics Committee Universiti Kebangsaan Malaysia (FF-2020-360). Written informed consent was obtained from all participants prior to the study.

Ethical Approval

Research Ethics Committee Universiti Kebangsaan Malaysia.

• References

• 1 Hussein Z, Kamaruddin NA, Chan SP, Jain A, Uppal S, Bebakar WMW. HAT study investigators in Malaysia. Hypoglycemia awareness among insulin-treated patients with diabetes in Malaysia: a cohort subanalysis of the HAT study. Diabetes Res Clin Pract 2017; 133: 40-49
• 2 Cryer PE, Axelrod L, Grossman AB. et al; Endocrine Society. Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2009; 94 (03) 709-728
• 3 Schwartz NS, Clutter WE, Shah SD, Cryer PE. Glycemic thresholds for activation of glucose counterregulatory systems are higher than the threshold for symptoms. J Clin Invest 1987; 79 (03) 777-781
• 4 Mitrakou A, Ryan C, Veneman T. et al. Hierarchy of glycemic thresholds for counterregulatory hormone secretion, symptoms, and cerebral dysfunction. Am J Physiol 1991; 260 (1 Pt 1): E67-E74
• 5 Ramnanan CJ, Edgerton DS, Kraft G, Cherrington AD. Physiologic action of glucagon on liver glucose metabolism. Diabetes Obes Metab 2011; 13 (Suppl. 01) 118-125
• 6 Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med 2010; 27 (02) 136-142
• 7 Reno CM, Litvin M, Clark AL, Fisher SJ. Defective counterregulation and hypoglycemia unawareness in diabetes: mechanisms and emerging treatments. Endocrinol Metab Clin North Am 2013; 42 (01) 15-38
• 8 Nakhleh A, Shehadeh N. Hypoglycemia in diabetes: an update on pathophysiology, treatment, and prevention. World J Diabetes 2021; 12 (12) 2036-2049
• 9 Asvold BO, Sand T, Hestad K, Bjørgaas MR. Cognitive function in type 1 diabetic adults with early exposure to severe hypoglycemia: a 16-year follow-up study. Diabetes Care 2010; 33 (09) 1945-1947
• 10 Bree AJ, Puente EC, Daphna-Iken D, Fisher SJ. Diabetes increases brain damage caused by severe hypoglycemia. Am J Physiol Endocrinol Metab 2009; 297 (01) E194-E201
• 11 Larsen A, Højlund K, Poulsen MK, Madsen RE, Juhl CB. Hypoglycemia-associated electroencephalogram and electrocardiogram changes appear simultaneously. J Diabetes Sci Technol 2013; 7 (01) 93-99
• 12 Desouza CV, Bolli GB, Fonseca V. Hypoglycemia, diabetes, and cardiovascular events. Diabetes Care 2010; 33 (06) 1389-1394
• 13 Wright RJ, Newby DE, Stirling D, Ludlam CA, Macdonald IA, Frier BM. Effects of acute insulin-induced hypoglycemia on indices of inflammation: putative mechanism for aggravating vascular disease in diabetes. Diabetes Care 2010; 33 (07) 1591-1597
• 14 Davis IC, Ahmadizadeh I, Randell J, Younk L, Davis SN. Understanding the impact of hypoglycemia on the cardiovascular system. Expert Rev Endocrinol Metab 2017; 12 (01) 21-33
• 15 Stahn A, Pistrosch F, Ganz X. et al. Relationship between hypoglycemic episodes and ventricular arrhythmias in patients with type 2 diabetes and cardiovascular diseases: silent hypoglycemias and silent arrhythmias. Diabetes Care 2014; 37 (02) 516-520
• 16 Reno CM, Daphna-Iken D, Chen YS, VanderWeele J, Jethi K, Fisher SJ. Severe hypoglycemia-induced lethal cardiac arrhythmias are mediated by sympathoadrenal activation. Diabetes 2013; 62 (10) 3570-3581
• 17 Seaquist ER, Anderson J, Childs B. et al; American Diabetes Association, Endocrine Society. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. J Clin Endocrinol Metab 2013; 98 (05) 1845-1859
• 18 Suh SW, Gum ET, Hamby AM, Chan PH, Swanson RA. Hypoglycemic neuronal death is triggered by glucose reperfusion and activation of neuronal NADPH oxidase. J Clin Invest 2007; 117 (04) 910-918
• 19 Lund A. On the role of the gut in diabetic hyperglucagonaemia. Dan Med J 2017; 64 (04) B5340
• 20 Boden G, Soriano M, Hoeldtke RD, Owen OE. Counterregulatory hormone release and glucose recovery after hypoglycemia in non-insulin-dependent diabetic patients. Diabetes 1983; 32 (11) 1055-1059
• 21 Aronoff SL, Berkowitz K, Shreiner B, Want L. Glucose Metabolism and Regulation: Beyond Insulin and Glucagon. Diabetes Spectr 2004; 17 (03) 183-190
• 22 Amiel SA, Simonson DC, Tamborlane WV, DeFronzo RA, Sherwin RS. Rate of glucose fall does not affect counterregulatory hormone responses to hypoglycemia in normal and diabetic humans. Diabetes 1987; 36 (04) 518-522
• 23 Tesfaye N, Seaquist ER. Neuroendocrine responses to hypoglycemia. Ann N Y Acad Sci 2010; 1212: 12-28
• 24 Amiel SA, Sherwin RS, Simonson DC, Tamborlane WV. Effect of intensive insulin therapy on glycemic thresholds for counterregulatory hormone release. Diabetes 1988; 37 (07) 901-907
• 25 Blaabjerg L, Juhl CB. Hypoglycemia-induced changes in the electroencephalogram: an overview. J Diabetes Sci Technol 2016; 10 (06) 1259-1267
• 26 Pramming S, Thorsteinsson B, Stigsby B, Binder C. Glycaemic threshold for changes in electroencephalograms during hypoglycaemia in patients with insulin dependent diabetes. Br Med J (Clin Res Ed) 1988; 296 (6623): 665-667
• 27 Synek VM. The low-voltage electroencephalogram. Clin Electroencephalogr 1983; 14 (02) 102-105
• 28 Lindström T, Jorfeldt L, Tegler L, Arnqvist HJ. Hypoglycaemia and cardiac arrhythmias in patients with type 2 diabetes mellitus. Diabet Med 1992; 9 (06) 536-541

Publikationsverlauf

Artikel online veröffentlicht:
31. Oktober 2025